About Caring4Cancer

 
Caring4Cancer's mission is to provide a complete source of knowledge and support for people with cancer, empowering them with the expertise, strength and hope they need to live their lives to the fullest. Caring4Cancer combines a virtual encyclopedia of cancer information with a collection of powerful tools that help patients take an active role in managing their disease. Our world-renowned Oncology Advisory Board reviews our content for accuracy and timeliness.

At Caring4Cancer, you can:

  • Shape the content to match your specific cancer type, diagnosis, and phase of treatment or recovery
  • Interact with other patients and experts through our message boards
  • Keep track of your symptoms, treatments, and appointments with a secure Patient Health Record and Symptom Tracker
  • View online videos right in your doctor’s office or in the comfort of your own home
  • Sign up for e-newsletters tailored to your interests and needs.
  • Create your own personal web page where you can keep a personal journal, exchange messages of encouragement, share pictures, and more.

Hundreds of oncology practices are now prescribing Caring4Cancer’s educational and interactive tools to their patients, just as they prescribe medication or therapy.However, the content at Caring4Cancer is not intended to be a substitute for professional medical advice, diagnosis, or treatment. For information on how to contact us, please click here.

This content was last reviewed August 15, 2010 by Dr. Reshma L. Mahtani.
Latest Cancer News
REFILE: Komen charity under microscope for funding, science

February 8, 2012 — NEW YORK (Reuters) - The Susan G. Komen for the Cure charity defines its mission as finding a cure for breast cancer. In recent years, however, it has cut by nearly half the proportion of fund-raising dollars it spends on grants to scientists working to understand the causes and develop effective new treatments for the disease.

US FDA panel votes against wider use of Amgen drug

February 8, 2012 — WASHINGTON (Reuters) - An advisory panel on Wednesday recommended that U.S. health regulators reject the use of Amgen Inc's drug Xgeva to delay the spread of prostate cancer to the bone, dimming the chance of a wider use for one of the company's key growth drivers.

US consumers want tougher probe of engineered salmon

February 8, 2012 — WASHINGTON (Reuters) - Three U.S. consumer groups petitioned the Food and Drug Administration on Tuesday to subject a new genetically engineered salmon to a more rigorous review process than is now in place before the fish can be approved as safe to eat.

Select news items provided by Reuters Health